Baidu
map

BMJ:Sotagliflozin用于I型糖尿病效果显著

2019-04-10 MedSci MedSci原创

研究认为,Sotagliflozin可改善I型糖尿病患者血糖及非血糖结果,降低低血糖风险

近日研究人员就双葡萄糖转运体(SGLT)1/2抑制剂Sotagliflozin对I性糖尿病患者的疗效和安全性进行了考察。

本次研究是对先前随机临床研究的荟萃分析,收集截止2019年1月的相关研究数据,随机对照试验评估Sotagliflozin与活性对照剂或安慰剂对18岁以上的I型糖尿病患者的血糖和非血糖结果的影响以及不良事件。

本次研究包含6个随机研究,739个记录, 3238名患者,研究持续4-52周。研究证实,Sotagliflozin可降低糖化血红蛋白(HbA1c,平均减少0.34%)、空腹血糖(平均减少16.98 mg/dL)、餐后2小时血糖(平均减少39.2 mg/dL)以及每日总、基础和推注胰岛素剂量(分别减少8.99%、8.03%以及9.14%)。Sotagliflozin可改善一段时间内或连续血糖监测参数(平均差异9.73%)、降低体重(减少3.54%)、降低动脉血压(3.85mmHg)以及蛋白尿(白蛋白/肌酐比减少14.57 mg/g)。Sotagliflozin可减少低血糖以及严重低血糖风险,但导致酮酸中毒、生殖感染以及腹泻不良事件风险增加,基线HbA1c及胰岛素用量与酮酸中毒风险相关。400 mg/d剂量组的治疗效果优于200 mg/d剂量组,且不会增加不良事件风险。总体证据质量中高,但关于血管事件和死亡的相关证据质量较低。

研究认为,Sotagliflozin可改善I型糖尿病患者血糖及非血糖结果,降低低血糖风险。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738276, encodeId=d16c1e382760a, content=<a href='/topic/show?id=bf011655eff' target=_blank style='color:#2F92EE;'>#Sotagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16557, encryptionId=bf011655eff, topicName=Sotagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fe434414406, createdName=124987c6m47暂无昵称, createdTime=Sat Jun 29 16:26:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848717, encodeId=86571848e1783, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Sep 06 23:26:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042371, encodeId=531410423e19d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 10 13:26:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046793, encodeId=feca1046e93e8, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 10 13:26:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738276, encodeId=d16c1e382760a, content=<a href='/topic/show?id=bf011655eff' target=_blank style='color:#2F92EE;'>#Sotagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16557, encryptionId=bf011655eff, topicName=Sotagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fe434414406, createdName=124987c6m47暂无昵称, createdTime=Sat Jun 29 16:26:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848717, encodeId=86571848e1783, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Sep 06 23:26:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042371, encodeId=531410423e19d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 10 13:26:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046793, encodeId=feca1046e93e8, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 10 13:26:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-09-06 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1738276, encodeId=d16c1e382760a, content=<a href='/topic/show?id=bf011655eff' target=_blank style='color:#2F92EE;'>#Sotagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16557, encryptionId=bf011655eff, topicName=Sotagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fe434414406, createdName=124987c6m47暂无昵称, createdTime=Sat Jun 29 16:26:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848717, encodeId=86571848e1783, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Sep 06 23:26:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042371, encodeId=531410423e19d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 10 13:26:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046793, encodeId=feca1046e93e8, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 10 13:26:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-04-10 misszhang

    谢谢MedSci提供最新的资讯

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1738276, encodeId=d16c1e382760a, content=<a href='/topic/show?id=bf011655eff' target=_blank style='color:#2F92EE;'>#Sotagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16557, encryptionId=bf011655eff, topicName=Sotagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fe434414406, createdName=124987c6m47暂无昵称, createdTime=Sat Jun 29 16:26:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848717, encodeId=86571848e1783, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Sep 06 23:26:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042371, encodeId=531410423e19d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 10 13:26:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046793, encodeId=feca1046e93e8, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 10 13:26:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-04-10 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

中国科学家首创I型糖尿病全新治疗性DNA疫苗

日前,解放军总医院第五医学中心免疫室主任奚永志团队申报的《基于B7-1-PE40KDEL外毒素融合基因的DNA疫苗及其用途》正式获得国际标准“三方”发明专利授权。该成果是具有完全自主知识产权的原创性成果,也是我国全新治疗性DNA疫苗领域获得的首个国际标准“三方”发明专利授权,它代表中国在I型糖尿病生物治疗新药研究领域取得重要突破,也标志着我国在全新型治疗性基因疫苗的创新研究上走在了世界前列。治疗性

一文读懂高渗性非酮症糖尿病昏迷

患者男性,67岁,广东人,因多尿、多饮2周,昏迷4小时于8月31日入院。

一文读懂与糖尿病诊断治疗相关的检测指标

早期发现、诊断并正确治疗糖尿病(DM)十分重要,而DM的诊断、分型、病情的进展、并发症的判断及预后都与实验室检查密切相关。检测项目的选择、检测结果的正确评价及检测时的注意事项都直接关系到患者的疗效。本文对临床常用的DM检测指标进行了总结,分为生化检查、尿液检查、免疫学检查、激素检查几个方面,供您参考。一、生化检查01葡萄糖测定参考值:空腹血清/血浆葡萄糖3.9~6.1 mmol/L临床应用患者

DIABETOLOGIA:冠状动脉钙化检测在1型糖尿病突发冠状动脉疾病风险预测中的作用

本研究调查了292名参与者,并试图利用匹兹堡糖尿病并发症流行病学(EDC)研究的数据,评估冠状动脉钙化(CAC)的作用及其在预测1型糖尿病患者发生冠状动脉疾病(CAD)中的进展。

Baidu
map
Baidu
map
Baidu
map